KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.

Srdan Verstovsek, Haifa Kathrin Al-Ali, John Mascarenhas, Andrew Perkins, Alessandro Maria Vannucchi, Sanjay R Mohan, Bart L Scott, Dariusz Woszczyk, Steffen Koschmieder, Regina García-Delgado, Rejtő László, Jesse S McGreivy, Wayne P Rothbaum, Jean-Jacques Kiladjian

Future Oncol 10.2217/fon-2022-0901

PMID36416118
PMCID-
DOI10.2217/fon-2022-0901
发表日期2022-11-23
摘要

摘要

Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with limited impact on underlying disease pathophysiology. Murine double minute 2 (MDM2), a negative regulator of p53, is overexpressed in circulating malignant CD34+ MF cells. The oral MDM2 inhibitor navtemadlin (KRT-232) restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins. Navtemadlin demonstrated promising clinical and disease-modifying activity and acceptable safety in a phase II study in patients with relapsed/refractory MF. The randomized phase III BOREAS study compares the efficacy and safety of navtemadlin to best available therapy in patients with MF that is relapsed/refractory to JAK inhibitor treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。